目的:对他克莫司治疗面部脂溢性皮炎的疗效和安全性进行系统评价。方法:检索Pubmed、Embase、Cochrane图书馆、美国临床试验数据库、知网、万方、CBM等数据库,纳入各数据库自建库以来至2023年4月有关他克莫司治疗面部脂溢性皮炎的随机...目的:对他克莫司治疗面部脂溢性皮炎的疗效和安全性进行系统评价。方法:检索Pubmed、Embase、Cochrane图书馆、美国临床试验数据库、知网、万方、CBM等数据库,纳入各数据库自建库以来至2023年4月有关他克莫司治疗面部脂溢性皮炎的随机对照试验(RCT)。纳入的随机对照试验质量通过Cochrane系统评估手册5.1.0进行评估,使用RevMan 5.4软件进行荟萃分析。结果:本研究共纳入5篇文献,共388例患有面部脂溢性皮炎的患者。研究的结果表明,与对照组相比,试验组治疗的总有效率更高(OR = 2.56, 95% CI: 1.55~4.53, P = 0.0004),试验组与对照组的不良反应发生情况差异没有统计学意义(OR = 1.00, 95% CI: 0.29~3.41, P = 0.99),治疗前后的临床症状积分结果试验组高于对照组(MD = 1.83, 95% CI: 1.23~2.42, P P = 0.99),故猜测不良反应的发生可能与其他一些因素有关。结论:他克莫司治疗面部脂溢性皮炎的临床效果显著,可有效改善患者的临床症状,安全性较高,但未来仍需要多中心、大样本的RCT加以证实。Objective: To systematically evaluate the efficacy and safety of tacrolimus in the treatment of facial seborrheic dermatitis. Methods: Pubmed, Embase, the Cochrane Library, the American Clinical Trials Database, CNKI, Wanfang, CBM and other databases were searched, and randomised controlled trials (RCTs) of tacrolimus for the treatment of facial seborrheic dermatitis were included in each database from its inception until April 2023. The quality of the included randomised controlled trials was assessed by the Cochrane Handbook for Systematic Reviews 5.1.0 and meta-analyses were performed using RevMan 5.4 software. Results: A total of 388 patients suffering from facial seborrheic dermatitis were included in this study from five publications. The results of the study showed that the overall efficacy of the treatment was higher in the test group compared to the control group (OR = 2.56, 95% CI: 1.55~4.53, P = 0.0004), the difference in the incidence of adverse effects between the test group and the control group was not statistically significant (OR = 1.00, 95% CI: 0.29~3.41, P = 0.99), and the pre- and post-treatment clinical symptoms Score results of the experimental group was higher than that of the control group (MD = 1.83, 95% CI: 1.23~2.42, P P = 0.99), therefore, it was speculated that the occurrence of adverse reactions may be related to some other factors. Conclusion: The clinical efficacy of tacrolimus in the treatment of facial seborrheic dermatitis is significant, which can effectively improve the clinical symptoms of patients and has a high safety profile, but it still needs to be confirmed by multicentre, large-sample RCTs in the future.展开更多
目的:通过美国FDA不良事件报告系统(FAERS)数据库,挖掘噻托溴铵心血管不良事件信号,为用药监护提供依据。方法:采用报告比值比法(ROR)对FAERS数据库中于2004年第一季度至2023年第三季度上报的噻托溴铵心血管不良事件进行挖掘及分析。结...目的:通过美国FDA不良事件报告系统(FAERS)数据库,挖掘噻托溴铵心血管不良事件信号,为用药监护提供依据。方法:采用报告比值比法(ROR)对FAERS数据库中于2004年第一季度至2023年第三季度上报的噻托溴铵心血管不良事件进行挖掘及分析。结果:共获得噻托溴铵心血管不良事件报告3881例,年龄主要在65~75岁,女性多于男性,报告国家以美国和加拿大为主。采用ROR法共得到噻托溴铵心血管不良事件信号19个,主要表现为心肌梗死、房颤、充血性心力衰竭等。结论:噻托溴铵引发心血管不良事件存在一定的风险,临床使用时应加强早期监测。Objective: To investigate and assess the risk signals of tiotropium bromide cardiovascular adverse events through the US FDA Adverse Event Reporting System (FAERS) database. Methods: To mine and analyze the cardiovascular adverse events reported from the first quarter of 2004 to the third quarter of 2023 using the reported odds ratio (ROR). Results: A total of 3881 cardiovascular adverse events of tiotropium bromide were reported, mainly aged from 65 to 75 years, more women than men, and the reported countries were mainly the United States and Canada. A total of 19 cardiovascular adverse event signals of tiotropium bromide were obtained by ROR method, mainly manifested as myocardial infarction, atrial fibrillation, and congestive heart failure. Conclusion: Tiotropium bromide has a certain risk of cardiovascular adverse events, and early monitoring should be strengthened in clinical use.展开更多
目的:基于网络药理学和分子对接方法分析附子回阳救逆的具体作用机制,为新药研发及临床用药提供参考。方法:通过TCMSP、ETCM、HERB、SymMap数据库获取附子的主要化学成分,根据ADME筛选活性成分;通过STP数据库获取主要成分对应靶点;通过G...目的:基于网络药理学和分子对接方法分析附子回阳救逆的具体作用机制,为新药研发及临床用药提供参考。方法:通过TCMSP、ETCM、HERB、SymMap数据库获取附子的主要化学成分,根据ADME筛选活性成分;通过STP数据库获取主要成分对应靶点;通过Gencards、OMIM数据库获取疾病主要靶点,利用String平台进行蛋白质相互作用分析,构建PPI网络并挖掘网络中潜在的蛋白质功能模块。采用DAVID数据库平台分析“药物–成分–靶点”及其参与的生物过程及通路,最后通过AutoDock Vina进行分子对接验证。结果:附子回阳救逆的核心活性成分为石防风素、多根乌头碱、去甲乌药碱,核心靶点有EGFR、MAPK1、MAPK3等,分子对接验证亦显示靶点与成分的结合活性较好。通路主要作用于cAMP信号通路、MAPK信号通路和PI3K-Akt信号通路。结论:本研究对附子回阳救逆传统功效进行了全面的解释,为后续基础研究提供参考。Objctive: Based on network pharmacology and molecular docking methods, to analyze the specific mechanism of fuzi bring back yang and rescue from the collapse, so as to provide reference for new drug development and clinical use. Methods: The principal chemical components of fuzi were obtained through TCMSP, ETCM, HERB, and SymMap databases, and the active ingredients were screened according to ADME;the corresponding targets of the components were searched on STP database and the important targets of diseases were obtained through the Gencards and OMIM databases. The intersection of compound target and disease target was obtained and the coincidence target was imported into STRING database to construct a PPI network. The DAVID database platform was used to analyze “drug-ingredient-target” and the biological processes and pathways involved, and finally the molecular docking verification was carried out through AutoDock Vina. Results: The core active ingredients of Fuzi bring back yang and rescue from the collapse are deltoin, karakoline, (R)-norcoclaurine. The protein with a higher degree in the PPI network is EGFR, MAPK1, MAPK3. Molecular docking verification also shows the binding activity between the target and the ingredients better. The signaling pathways mainly include cAMP, MAPK and PI3K-Akt signaling pathway. Conclusion: This study reveals a comprehensive explanation of the traditional efficacy of fuzi huiyangjiuni, and provides a reference for subsequent basic research.展开更多
文摘目的:对他克莫司治疗面部脂溢性皮炎的疗效和安全性进行系统评价。方法:检索Pubmed、Embase、Cochrane图书馆、美国临床试验数据库、知网、万方、CBM等数据库,纳入各数据库自建库以来至2023年4月有关他克莫司治疗面部脂溢性皮炎的随机对照试验(RCT)。纳入的随机对照试验质量通过Cochrane系统评估手册5.1.0进行评估,使用RevMan 5.4软件进行荟萃分析。结果:本研究共纳入5篇文献,共388例患有面部脂溢性皮炎的患者。研究的结果表明,与对照组相比,试验组治疗的总有效率更高(OR = 2.56, 95% CI: 1.55~4.53, P = 0.0004),试验组与对照组的不良反应发生情况差异没有统计学意义(OR = 1.00, 95% CI: 0.29~3.41, P = 0.99),治疗前后的临床症状积分结果试验组高于对照组(MD = 1.83, 95% CI: 1.23~2.42, P P = 0.99),故猜测不良反应的发生可能与其他一些因素有关。结论:他克莫司治疗面部脂溢性皮炎的临床效果显著,可有效改善患者的临床症状,安全性较高,但未来仍需要多中心、大样本的RCT加以证实。Objective: To systematically evaluate the efficacy and safety of tacrolimus in the treatment of facial seborrheic dermatitis. Methods: Pubmed, Embase, the Cochrane Library, the American Clinical Trials Database, CNKI, Wanfang, CBM and other databases were searched, and randomised controlled trials (RCTs) of tacrolimus for the treatment of facial seborrheic dermatitis were included in each database from its inception until April 2023. The quality of the included randomised controlled trials was assessed by the Cochrane Handbook for Systematic Reviews 5.1.0 and meta-analyses were performed using RevMan 5.4 software. Results: A total of 388 patients suffering from facial seborrheic dermatitis were included in this study from five publications. The results of the study showed that the overall efficacy of the treatment was higher in the test group compared to the control group (OR = 2.56, 95% CI: 1.55~4.53, P = 0.0004), the difference in the incidence of adverse effects between the test group and the control group was not statistically significant (OR = 1.00, 95% CI: 0.29~3.41, P = 0.99), and the pre- and post-treatment clinical symptoms Score results of the experimental group was higher than that of the control group (MD = 1.83, 95% CI: 1.23~2.42, P P = 0.99), therefore, it was speculated that the occurrence of adverse reactions may be related to some other factors. Conclusion: The clinical efficacy of tacrolimus in the treatment of facial seborrheic dermatitis is significant, which can effectively improve the clinical symptoms of patients and has a high safety profile, but it still needs to be confirmed by multicentre, large-sample RCTs in the future.
文摘目的:通过美国FDA不良事件报告系统(FAERS)数据库,挖掘噻托溴铵心血管不良事件信号,为用药监护提供依据。方法:采用报告比值比法(ROR)对FAERS数据库中于2004年第一季度至2023年第三季度上报的噻托溴铵心血管不良事件进行挖掘及分析。结果:共获得噻托溴铵心血管不良事件报告3881例,年龄主要在65~75岁,女性多于男性,报告国家以美国和加拿大为主。采用ROR法共得到噻托溴铵心血管不良事件信号19个,主要表现为心肌梗死、房颤、充血性心力衰竭等。结论:噻托溴铵引发心血管不良事件存在一定的风险,临床使用时应加强早期监测。Objective: To investigate and assess the risk signals of tiotropium bromide cardiovascular adverse events through the US FDA Adverse Event Reporting System (FAERS) database. Methods: To mine and analyze the cardiovascular adverse events reported from the first quarter of 2004 to the third quarter of 2023 using the reported odds ratio (ROR). Results: A total of 3881 cardiovascular adverse events of tiotropium bromide were reported, mainly aged from 65 to 75 years, more women than men, and the reported countries were mainly the United States and Canada. A total of 19 cardiovascular adverse event signals of tiotropium bromide were obtained by ROR method, mainly manifested as myocardial infarction, atrial fibrillation, and congestive heart failure. Conclusion: Tiotropium bromide has a certain risk of cardiovascular adverse events, and early monitoring should be strengthened in clinical use.
文摘目的:基于网络药理学和分子对接方法分析附子回阳救逆的具体作用机制,为新药研发及临床用药提供参考。方法:通过TCMSP、ETCM、HERB、SymMap数据库获取附子的主要化学成分,根据ADME筛选活性成分;通过STP数据库获取主要成分对应靶点;通过Gencards、OMIM数据库获取疾病主要靶点,利用String平台进行蛋白质相互作用分析,构建PPI网络并挖掘网络中潜在的蛋白质功能模块。采用DAVID数据库平台分析“药物–成分–靶点”及其参与的生物过程及通路,最后通过AutoDock Vina进行分子对接验证。结果:附子回阳救逆的核心活性成分为石防风素、多根乌头碱、去甲乌药碱,核心靶点有EGFR、MAPK1、MAPK3等,分子对接验证亦显示靶点与成分的结合活性较好。通路主要作用于cAMP信号通路、MAPK信号通路和PI3K-Akt信号通路。结论:本研究对附子回阳救逆传统功效进行了全面的解释,为后续基础研究提供参考。Objctive: Based on network pharmacology and molecular docking methods, to analyze the specific mechanism of fuzi bring back yang and rescue from the collapse, so as to provide reference for new drug development and clinical use. Methods: The principal chemical components of fuzi were obtained through TCMSP, ETCM, HERB, and SymMap databases, and the active ingredients were screened according to ADME;the corresponding targets of the components were searched on STP database and the important targets of diseases were obtained through the Gencards and OMIM databases. The intersection of compound target and disease target was obtained and the coincidence target was imported into STRING database to construct a PPI network. The DAVID database platform was used to analyze “drug-ingredient-target” and the biological processes and pathways involved, and finally the molecular docking verification was carried out through AutoDock Vina. Results: The core active ingredients of Fuzi bring back yang and rescue from the collapse are deltoin, karakoline, (R)-norcoclaurine. The protein with a higher degree in the PPI network is EGFR, MAPK1, MAPK3. Molecular docking verification also shows the binding activity between the target and the ingredients better. The signaling pathways mainly include cAMP, MAPK and PI3K-Akt signaling pathway. Conclusion: This study reveals a comprehensive explanation of the traditional efficacy of fuzi huiyangjiuni, and provides a reference for subsequent basic research.
